Regulators of medical technologies are facing increasing pressure to make their deliberations concerning the benefits and risk more transparent. Both benefits and risks are often measured via multiple competing outcomes. Hence, MCDA models like the Analytic Hierarchy/Network Process are valuable tools in quantifying decision trade-offs. The objective of this paper is to demonstrate the use of MCDA models for benefit-risk assessment and the use of sensitivity analysis to assess the impact of uncertainty and patient heterogeneity.
Uncertainty in MCDA models:
Structural uncertainty Uncertainty about the assumptions made in the design of an MCDA decision structure and the methods for elicitation of responses E.g. which attributes were taken and which decision objective.
Stochastic uncertainty
•Heterogeneity: uncertainty about the treatment preferences in subgroups of the population.
•Imprecision: parameter uncertainty, i.e. the uncertainty around the estimation of an individual parameter.
•Uncertainty "sensu stricto": uncertainty about the decision makers' knowledge and confidence about the subject matter.
Solutions to stochastic uncertainty in preference data:
• Sampling approach and sample size Include representative sample of respondents for elicitation. Decide on group panel approach (<15 respondents) or survey methods. Analyze preference heterogeneity.
• Probabilistic Sensitivity Analysis (PSA) and resampling Use of PSA on preference data and clinical performance data, either with or without resampling methods. Small group decision studies require resampling of preference data.
• PSA based on fuzzy data sets Calibrate experts to generate fuzzy data sets. Calibration can be done by asking for the magnitude of uncertainty people have in providing their scores. Approach 1: Deterministic sensitivity analysis of the "impact of decision criteria" and "performance" by manually adjusting priorities Approach 2 and 3: Probabilistic Sensitivity Analysis of (1) criteria weights and (2) criteria weights and performance of antidepressants Base-case analysis Sensitivity analysis on "treatment response"
Sensitivity analysis on drug performance on HRQoL OR transformed to priority weights Probabilistic Sensitivity Analysis for criteria weights. Criteria weights (n=12 patients) were resampled using bootstrapping. Base case ORs on drug performance were obtained from the literature. Drug treatment preferences were calculated.
Probabilistic Sensitivity Analysis for criteria weights and drug performance. Criteria weights (n=12 patients) were resampled using bootstrapping. Drug performance was sampled from OR distributions for the three separate drugs.
Probabilistic Sensitivity Analysis for criteria weights excluding "relapse" and "HRQoL". These were not given a preference weight because of insufficient data on drug performance. Criteria weights and drug performances were resampled using bootstrapping (see other cases) November, 8 2011 11-12 AM 
